P2‐418: presubiculum volume loss may mediate vascular cognitive impairment in preclinical stage

Dongwei Lu,Dong Sun,Junjian Zhang
DOI: https://doi.org/10.1016/j.jalz.2018.06.1110
2006-01-01
Alzheimer s & Dementia
Abstract:Hippocampus subfield volume loss is linked with ageing and Alzheimer's Disease process. However, less is known for younger adults suffering from vascular risk factors(VRFs) in preclinical dementia and CVD stage. The aim of study is to investigate the effect of total VRFs on hippocampus subfield volume change and clinical cognition impairment. The total burden of VRFs in non-dementia and CVD free middle-aged subjects was assessed by Framingham Cardiovasular risk factor scale and then grouped into low-risk(<10%), medium-risk(10%-20%) and high-risk(>20%) group. A battery of cognitive tests was used to assess various domains of cognitive function. Volumetric analysis was performed using 3D T1-weighted MPRAGE image. Freesurfer 6.0 was used for hippocampus parcellation. Hippocampal subfield volumes were adjusted by intracranial volume. Cognitive tests were transformed to Z-scores. Partial Correlation and Linear Regression Model were used, with age, gender, education years, ApoE4 positive status as covariants. After excluding 2 badly segmentated subjects, 91 (aged 57.89±5.04) were included in this study. Total Framingham score was significant in the left presubiculum(Beta=-.284,p=.033).When specifically looking into the gender, men tended to suffer hippocampus subfield loss in CA1(Beta=.399,p=.048), and fissure(Beta=.432,p=.027).low-risk group is significantly better than high-risk group in working memory(p=.016) and better than medium-risk group in visual attention ability (TrailMakingB)(p=.042) after Bonferroni correction for multiple comparison. Presubiculum was significantly impaired with the accumulation of VRFs. Working memory and visual attention were two affected cognitive domains in our younger cohort. Vascular cognitive impairment may suffer another pathology process but still share some common features with Alzheimer's Disease in preclinical stage.
What problem does this paper attempt to address?